JAK inhibitors in refractory dermatomyositis: A case series

Author:

Corbella‐Bagot L.1,Bosch‐Amate X.1,Gimeno‐Ribes E.1,Gil‐Lianes J.1,Giavedoni P.1,Milisenda J. C.23,Prieto‐González S.45,Hurtado García R.6,Mascaró J. M.1

Affiliation:

1. Department of Dermatology, Hospital Clínic de Barcelona University of Barcelona Barcelona Catalunya Spain

2. Muscle Research Unit, Internal Medicine Service Hospital Clinic Barcelona Catalunya Spain

3. CIBERER, IDIBAPS and University of Barcelona Barcelona Catalunya Spain

4. Department of Internal Medicine, Hospital Clínic de Barcelona University of Barcelona Barcelona Spain

5. Department of Autoimmune Diseases, Hospital Clínic de Barcelona University of Barcelona Barcelona Spain

6. Department of Internal Medicine Hospital Vega Baja Orihuela Spain

Abstract

AbstractThis retrospective cohort study assessed the efficacy and safety of Janus kinase (JAK) inhibitors, tofacitinib and baricitinib, in 14 patients with refractory dermatomyositis (DM), a multisystemic autoimmune disorder with limited therapeutic options. Results demonstrated a significant median decrease of 21 points and a 76% reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) scores, along with a complete resolution of muscular symptoms in 64% of the patients. JAK inhibitors were effective in managing refractory DM across various subtypes with mild and manageable adverse events.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3